Abbott (ABT) stock shrugs off Q3 results as spin-off looms
FROM THE WIRE · FINANCE.YAHOO.COM
Abbott Laboratories came into this Q3 2026 report with a rich valuation and a reputation as a dependable healthcare compounder, yet the stock had slipped over the last month. Today, the shares are only up about 0.8% despite comparable sales growth of roughly 7% and adjusted…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishResults in line with expectations and a planned Nutrition spin-off, with the shares slightly higher.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Abbott reports comparable sales growth of roughly 7%.
- 02Adjusted earnings per share were US$1.42.
- 03The plan includes spinning off the US$8.5b Nutrition unit.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets